Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says
Amgen's and Johnson & Johnson's erythropoietin survival studies cannot logistically include a tumor biopsy component, FDA's Oncologic Drugs Advisory Committee said May 4
Amgen's and Johnson & Johnson's erythropoietin survival studies cannot logistically include a tumor biopsy component, FDA's Oncologic Drugs Advisory Committee said May 4